ALLO
Price
$1.38
Change
-$0.02 (-1.43%)
Updated
Dec 26 closing price
Capitalization
310.13M
67 days until earnings call
Intraday BUY SELL Signals
ALNY
Price
$400.59
Change
-$0.10 (-0.02%)
Updated
Dec 26 closing price
Capitalization
52.92B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALLO vs ALNY

Header iconALLO vs ALNY Comparison
Open Charts ALLO vs ALNYBanner chart's image
Allogene Therapeutics
Price$1.38
Change-$0.02 (-1.43%)
Volume$2.2M
Capitalization310.13M
Alnylam Pharmaceuticals
Price$400.59
Change-$0.10 (-0.02%)
Volume$401.46K
Capitalization52.92B
ALLO vs ALNY Comparison Chart in %
ALLO
Daily Signal:
Gain/Loss:
ALNY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALLO vs. ALNY commentary
Dec 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Buy and ALNY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 27, 2025
Stock price -- (ALLO: $1.38 vs. ALNY: $400.59)
Brand notoriety: ALLO and ALNY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 90% vs. ALNY: 30%
Market capitalization -- ALLO: $310.13M vs. ALNY: $52.92B
ALLO [@Biotechnology] is valued at $310.13M. ALNY’s [@Biotechnology] market capitalization is $52.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.45B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileALNY’s FA Score has 2 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • ALNY’s FA Score: 2 green, 3 red.
According to our system of comparison, ALNY is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while ALNY’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 5 bearish.
  • ALNY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ALLO and ALNY are a good buy in the short-term.

Price Growth

ALLO (@Biotechnology) experienced а -2.82% price change this week, while ALNY (@Biotechnology) price change was +0.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.36%. For the same industry, the average monthly price growth was +0.27%, and the average quarterly price growth was +54.56%.

Reported Earning Dates

ALLO is expected to report earnings on Mar 04, 2026.

ALNY is expected to report earnings on Feb 12, 2026.

Industries' Descriptions

@Biotechnology (+0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($52.9B) has a higher market cap than ALLO($310M). ALNY YTD gains are higher at: 70.239 vs. ALLO (-35.211). ALNY has higher annual earnings (EBITDA): 187M vs. ALLO (-198.19M). ALNY has more cash in the bank: 2.73B vs. ALLO (252M). ALLO has less debt than ALNY: ALLO (77.1M) vs ALNY (1.31B). ALNY has higher revenues than ALLO: ALNY (3.21B) vs ALLO (0).
ALLOALNYALLO / ALNY
Capitalization310M52.9B1%
EBITDA-198.19M187M-106%
Gain YTD-35.21170.239-50%
P/E RatioN/A1335.30-
Revenue03.21B-
Total Cash252M2.73B9%
Total Debt77.1M1.31B6%
FUNDAMENTALS RATINGS
ALLO vs ALNY: Fundamental Ratings
ALLO
ALNY
OUTLOOK RATING
1..100
1079
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10013
SMR RATING
1..100
9729
PRICE GROWTH RATING
1..100
5150
P/E GROWTH RATING
1..100
10063
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALLO's Valuation (96) in the Biotechnology industry is in the same range as ALNY (100). This means that ALLO’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for ALLO (100). This means that ALNY’s stock grew significantly faster than ALLO’s over the last 12 months.

ALNY's SMR Rating (29) in the Biotechnology industry is significantly better than the same rating for ALLO (97). This means that ALNY’s stock grew significantly faster than ALLO’s over the last 12 months.

ALNY's Price Growth Rating (50) in the Biotechnology industry is in the same range as ALLO (51). This means that ALNY’s stock grew similarly to ALLO’s over the last 12 months.

ALNY's P/E Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for ALLO (100). This means that ALNY’s stock grew somewhat faster than ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOALNY
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
71%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 17 days ago
80%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 13 days ago
64%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALLO
Daily Signal:
Gain/Loss:
ALNY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TFPN26.170.04
+0.13%
Blueprint Chesapeake Multi-Asst Trnd ETF
VGM10.320.01
+0.10%
Invesco Trust Investment Grade Municipals
XIJN31.000.03
+0.10%
FT Vest U.S. Eq Bffr & Prm Inc ETF -June
URTH187.810.09
+0.05%
iShares MSCI World ETF
FXBY23.25-0.55
-2.31%
Foxby Corp.

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-1.43%
CRSP - ALLO
53%
Loosely correlated
-2.87%
BEAM - ALLO
52%
Loosely correlated
-0.57%
RXRX - ALLO
48%
Loosely correlated
-3.41%
MRNA - ALLO
46%
Loosely correlated
-4.73%
FATE - ALLO
45%
Loosely correlated
-0.99%
More

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with ARGX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
-0.02%
ARGX - ALNY
52%
Loosely correlated
-0.59%
SGMO - ALNY
42%
Loosely correlated
-4.49%
IONS - ALNY
37%
Loosely correlated
-0.89%
ALLO - ALNY
37%
Loosely correlated
-1.43%
BBIO - ALNY
36%
Loosely correlated
-0.95%
More